CancerDrs

Brain Cancer clinical trials in Wisconsin

17 actively recruiting brain cancer trials at 19 sites across Wisconsin.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Wisconsin:
  • Langlade Hospital and Cancer Center — Antigo, Wisconsin
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • Gundersen Lutheran Medical Center — La Crosse, Wisconsin
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…

Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Wisconsin:
  • Langlade Hospital and Cancer Center — Antigo, Wisconsin
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • Gundersen Lutheran Medical Center — La Crosse, Wisconsin
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Children's Hospital of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Wisconsin:
  • University Of Wisconsin - Madison — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …

Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Wisconsin:
  • Froedtert Hospital/Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

18F-FLUC PET/MR in Patients With Brain Mets

The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomogr…

Sponsor: University of Wisconsin, Madison
NCT ID: NCT06159335
Sites in Wisconsin:
  • University of Wisconsin — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Wisconsin:
  • Langlade Hospital and Cancer Center — Antigo, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Gundersen Lutheran Medical Center — La Crosse, Wisconsin
  • University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …

Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual app…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06319027
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Froedtert Menomonee Falls Hospital — Menomonee Falls, Wisconsin
  • Medical College of Wisconsin — Milwaukee, Wisconsin
  • Drexel Town Square Health Center — Oak Creek, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…

Sponsor: Bayer
NCT ID: NCT06914128
Sites in Wisconsin:
  • Froedtert Hospital - Clinical Cancer Center — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial

This phase II trial compares the effect of single fraction stereotactic radiosurgery to fractionated stereotactic radiosurgery for the treatment of patients with cancer that has spread to the brain (metastatic brain disease). Stereotactic …

Sponsor: Mayo Clinic
NCT ID: NCT05222620
Sites in Wisconsin:
  • Mayo Clinic Health System-Eau Claire Clinic — Eau Claire, Wisconsin
  • Mayo Clinic Health System-Franciscan Healthcare — La Crosse, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
View on ClinicalTrials.gov →
NA Recruiting Industry

REMASTer: REcurrent Brain Metastases After SRS Trial

Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS…

Sponsor: Monteris Medical
NCT ID: NCT05124912
Sites in Wisconsin:
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Recruiting Academic/Other

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical…

Sponsor: UMC Utrecht
NCT ID: NCT04075305
Sites in Wisconsin:
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors

The neurosurgical standard of care for treating a patient with a tumor invading hand primary motor cortex (M1) includes performing a craniotomy with intraoperative direct electrical stimulation (DES) mapping and to resect as much tumor as …

Sponsor: Medical College of Wisconsin
NCT ID: NCT05023434
Sites in Wisconsin:
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07